# IBI308 in Subjects With Advanced/Metastatic Solid Malignancies

> **NCT03568539** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 39 (actual)

## Conditions studied

- Advanced/Metastatic Solid Malignancies

## Interventions

- **DRUG:** IBI308

## Key facts

- **NCT ID:** NCT03568539
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-27
- **Primary completion:** 2020-11-09
- **Final completion:** 2020-12-07
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2021-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03568539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03568539, "IBI308 in Subjects With Advanced/Metastatic Solid Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03568539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*